Profile data is unavailable for this security.
About the company
Sinopharm Group Co Ltd is a China-based company principally engaged in pharmaceutical and medical devices distribution business. The Company operates its business through four segments. Pharmaceutical Distribution segment is engaged in the distribution of pharmaceutical products to hospitals, other distributors, retail pharmacy stores and clinics. Medical Devices segment is engaged in the distribution of medical devices, as well as provides installation and maintenance services. Retail Pharmacy segment is engaged in the operation of chain pharmacy stores. Other Business segment is engaged in the distribution of laboratory supplies, manufacture and distribution of chemical reagents, production and sale of pharmaceutical products.
- Revenue in HKD (TTM)644.36bn
- Net income in HKD9.78bn
- Incorporated2003
- Employees115.96k
- LocationSinopharm Group Co LtdSinopharm Group Building, No. 385, EastSHANGHAI 200023ChinaCHN
- Phone+86 2 123052299
- Fax+86 2 123052144
- Websitehttps://www.sinopharmgroup.com.cn/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China Resources Pharmaceutical Group Ltd | 264.31bn | 4.16bn | 38.76bn | 72.99k | 9.31 | 0.7809 | 3.28 | 0.1467 | 0.6626 | 0.6626 | 42.07 | 7.90 | 1.06 | 7.06 | 3.84 | 3,621,356.00 | 3.36 | 3.02 | 12.72 | 11.35 | 15.67 | 15.72 | 3.18 | 2.87 | 1.09 | 8.70 | 0.412 | 24.73 | 12.16 | 8.86 | 10.11 | 2.80 | 13.58 | 7.05 |
| Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd | 82.85bn | 4.43bn | 54.94bn | 28.05k | 12.99 | 1.45 | -- | 0.6632 | 2.52 | 2.52 | 47.25 | 22.68 | 1.01 | 6.70 | 4.70 | 2,739,343.00 | 5.67 | 5.90 | 10.56 | 12.40 | 18.07 | 18.70 | 5.63 | 5.56 | 1.35 | -- | 0.3132 | 30.02 | 6.68 | 12.32 | 2.25 | 3.34 | 27.75 | 12.05 |
| Shanghai Pharmaceuticals Holding Co Ltd | 284.91bn | 4.09bn | 67.03bn | 48.16k | 17.98 | 0.9773 | -- | 0.2353 | 1.03 | 1.03 | 71.57 | 18.92 | 1.25 | 7.10 | 3.38 | 5,485,870.00 | 2.40 | 3.53 | 6.33 | 9.34 | 11.34 | 13.21 | 1.92 | 2.66 | 1.07 | 7.55 | 0.403 | 32.89 | 12.21 | 10.35 | -32.92 | -0.5896 | 8.86 | 0.00 |
| Sinopharm Group Co Ltd | 644.36bn | 9.78bn | 68.65bn | 115.96k | 7.02 | 0.8522 | 3.27 | 0.1066 | 3.13 | 3.13 | 206.48 | 25.81 | 1.59 | 9.06 | 3.72 | 5,556,822.00 | 4.01 | 4.09 | 16.32 | 17.37 | 8.13 | 8.54 | 2.52 | 2.55 | 1.15 | 6.48 | 0.3801 | 30.02 | 8.05 | 11.61 | 6.19 | 9.18 | -7.26 | 8.10 |
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 02 Apr 2024 | 102.00m | 7.60% |
| Lazard Asset Management LLCas of 30 Jun 2023 | 93.99m | 7.01% |
| The Vanguard Group, Inc.as of 09 May 2024 | 51.32m | 3.83% |
| JPMorgan Asset Management (Asia Pacific) Ltd.as of 02 May 2024 | 43.25m | 3.22% |
| BlackRock Fund Advisorsas of 10 Jan 2024 | 32.84m | 2.45% |
| Dimensional Fund Advisors LPas of 09 May 2024 | 26.89m | 2.00% |
| Value Partners Ltd.as of 30 Jun 2023 | 23.49m | 1.75% |
| FIAM LLCas of 02 Apr 2024 | 22.91m | 1.71% |
| BlackRock Advisors (UK) Ltd.as of 10 Jan 2024 | 21.26m | 1.59% |
| Fidelity Investments Canada ULCas of 31 Mar 2024 | 21.16m | 1.58% |
